See more : Luminex Corporation (LMNX) Income Statement Analysis – Financial Results
Complete financial analysis of Candel Therapeutics, Inc. (CADL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Candel Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Condor Resources Inc. (CNRIF) Income Statement Analysis – Financial Results
- Helvetia Holding AG (HELN.SW) Income Statement Analysis – Financial Results
- Homerun Resources Inc. (AKAVF) Income Statement Analysis – Financial Results
- REC Silicon ASA (RNWEY) Income Statement Analysis – Financial Results
- ICICI Prudential Life Insurance Company Limited (ICICIPRULI.NS) Income Statement Analysis – Financial Results
Candel Therapeutics, Inc. (CADL)
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 125.00K | 125.00K | 125.00K | 125.00K |
| Cost of Revenue | 23.98M | 987.00K | 232.00K | 0.00 | 6.61M |
| Gross Profit | -23.98M | -862.00K | -107.00K | 125.00K | -6.48M |
| Gross Profit Ratio | 0.00% | -689.60% | -85.60% | 100.00% | -5,185.60% |
| Research & Development | 24.51M | 20.79M | 15.18M | 8.75M | 6.61M |
| General & Administrative | 13.72M | 14.06M | 10.67M | 5.18M | 2.56M |
| Selling & Marketing | 687.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.41M | 14.06M | 10.67M | 5.18M | 2.56M |
| Other Expenses | -24.51M | -48.00K | -1.08M | -624.00K | -571.00K |
| Operating Expenses | 14.41M | 34.80M | 24.78M | 13.31M | 8.59M |
| Cost & Expenses | 38.39M | 34.80M | 24.78M | 13.31M | 8.59M |
| Interest Income | 0.00 | 490.00K | 53.00K | 111.00K | 1.07M |
| Interest Expense | 514.00K | 490.00K | 53.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 960.00K | 987.00K | 232.00K | 91.00K | 43.00K |
| EBITDA | -37.43M | -17.32M | -25.49M | -13.72M | -8.20M |
| EBITDA Ratio | 0.00% | -40,835.20% | -19,534.40% | -6,792.00% | -6,063.20% |
| Operating Income | -38.39M | -34.72M | -25.73M | -13.81M | -9.04M |
| Operating Income Ratio | 0.00% | -27,777.60% | -20,580.80% | -11,048.00% | -7,229.60% |
| Total Other Income/Expenses | 452.00K | 15.93M | -10.40M | -3.87M | 797.00K |
| Income Before Tax | -37.94M | -18.79M | -36.12M | -17.68M | -8.24M |
| Income Before Tax Ratio | 0.00% | -15,035.20% | -28,899.20% | -14,144.00% | -6,592.00% |
| Income Tax Expense | 0.00 | -15.93M | 53.00K | 4.49M | -226.00K |
| Net Income | -37.94M | -2.87M | -36.18M | -22.17M | -8.01M |
| Net Income Ratio | 0.00% | -2,292.80% | -28,941.60% | -17,739.20% | -6,411.20% |
| EPS | -1.31 | -0.10 | -1.26 | -0.76 | -0.27 |
| EPS Diluted | -1.31 | -0.10 | -1.26 | -0.76 | -0.27 |
| Weighted Avg Shares Out | 28.94M | 28.82M | 28.69M | 29.15M | 29.15M |
| Weighted Avg Shares Out (Dil) | 28.94M | 28.82M | 28.69M | 29.15M | 29.15M |
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the fourth...
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a...
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and...
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (NSCLC) and a potentially registrational phase 3 clinical trial in prostate cancer Focusing on strategic key value drivers and catalysts, as a...
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer.
Candel Therapeutics pancreatic cancer therapy awarded FDA Fast Track Designation
Candel Therapeutics shares gained more than 37% after the biopharmaceutical firm announced that its pancreatic cancer therapeutic has received U.S. Food and Drug Administration (FDA) Fast Track Designation.
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
NEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and...
Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
NEEDHAM, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced a strategic restructuring to focus...
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the third quarter...
Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
NEEDHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (the Company or Candel) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today will present two posters during the 2023...
Source: https://incomestatements.info
Category: Stock Reports